HomepageGRFS • NASDAQ
add
Grifols
$ 8,96
Na sluitingstijd:(0,00%)0,00
$ 8,96
Gesloten: 26 feb, 16:35:26 GMT-5 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$ 9,25
Dag-range
$ 8,28 - $ 9,20
Jaar-range
$ 6,19 - $ 11,14
Beurswaarde
7,64 mld. USD
Gem. volume
490,34K
Koers/winst
13,90
Dividendrendement
1,96%
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (EUR) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 1,87 mld. | 4,04% |
Bedrijfskosten | 370,34 mln. | -1,71% |
Netto inkomsten | 126,96 mln. | 145,62% |
Netto winstmarge | 6,81 | 136,46% |
Winst per aandeel | — | — |
EBITDA | 484,03 mln. | 3,41% |
Effectief belastingtarief | 27,61% | — |
Balans
Totale activa
Totale passiva
| (EUR) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 825,48 mln. | 2,32% |
Totale activa | 19,85 mld. | -2,12% |
Totale passiva | 12,31 mld. | 0,14% |
Totaal aandelenvermogen | 7,55 mld. | — |
Uitstaande aandelen | 680,51 mln. | — |
Koers-boekwaardeverhouding | 1,22 | — |
Rendement op activa | 4,81% | — |
Rendement op kapitaal | 5,53% | — |
Kasstroom
Nettomutatie in liquide middelen
| (EUR) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 126,96 mln. | 145,62% |
Operationele kasstroom | 325,40 mln. | 8,61% |
Kasstroom uit beleggingen | -122,68 mln. | 37,53% |
Kasstroom uit financiering | -138,76 mln. | 91,08% |
Nettomutatie in liquide middelen | 62,27 mln. | 104,24% |
Vrije kasstroom | 369,19 mln. | 37,66% |
Over
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
CEO
Opgericht
18 nov 1940
Website
Werknemers
23.800